Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

(NASDAQ:ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, and its first year of annual ...

First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics ...

Argenx SE ARGX on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG). It is an autoimmune disorder where ...

Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action ...

The Wild Center features indoor exhibits with turtles and otters and unique outdoor adventures across 115 Adirondack acres.

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

SE (ARGNF) achieves 90% year-over-year sales growth and marks its first year of annual operating profitability, while navigating increased expenses and market challenges.

Full-year product net sales rose 90% to $4.15 billion from $2.19 billion in 2024, with fourth-quarter sales reaching $1.29 ...

Canon proves that VR really can enhance your images – and now its standard Dual Pixel sensors can turn regular photos into 3D ...

If you're curious about the rumors that rocked the gaming world, here are 10 gaming leaks that turned out to be true.